Myriad Genetics (MYGN) Q4 2024: 11% Revenue Growth Underpinned by Strategic AI Partnership and Product Innovation
Myriad Genetics sustained double-digit annual revenue growth driven by robust demand across hereditary cancer, prenatal, and pharmacogenomics testing, alongside a strategic AI collaboration expanding its oncology portfolio. The company is navigating reimbursement headwinds pragmatically while positioning for accelerated growth via innovation and operational execution. Upcoming product launches and expanded AI capabilities signal a transformative trajectory for 2025 and beyond.
Summary
- Strategic Expansion: Exclusive AI partnership with Pathomic enhances Myriad’s prostate cancer diagnostic offerings across the patient journey.
- Operational Momentum: Continued volume growth supported by EMR integrations and targeted commercial investments despite reimbursement challenges.
- Innovation Pipeline: New product launches and clinical studies underpin confidence in accelerating revenue growth and margin expansion.
Business Overview
Myriad Genetics is a molecular diagnostic and precision medicine company focused on genetic testing to assess disease risk, guide treatment decisions, and monitor disease progression. Its revenue is generated primarily through three segments: Women’s Health, Oncology, and Pharmacogenomics. The company’s portfolio includes hereditary cancer tests (e.g., MyRisk), tumor profiling assays (e.g., Prolaris, Precise Tumor), prenatal screening products (e.g., Prequel, Foresight), and pharmacogenomics testing (GeneSight), serving providers and patients across multiple care settings.
Performance Analysis
For the full year 2024, Myriad reported revenue of $838 million, an 11% increase year-over-year, showcasing sustained growth momentum across core segments. Fourth quarter revenue totaled $211 million, up 7% year-over-year, driven by 6% growth in hereditary cancer and 12% growth in prenatal testing. Pharmacogenomics testing revenue also rose 14% in the quarter despite a looming reimbursement headwind from UnitedHealthcare’s policy change.
Gross margin improved by 300 basis points to 71.7% in the quarter, reflecting higher revenue per test and enhanced laboratory efficiencies. Adjusted EBITDA reached $11 million in Q4 and $40 million for the full year, highlighting improving profitability amid increased R&D spending. Operating expenses rose due to investments in clinical evidence generation for upcoming products like FirstGene and Precise MRD, signaling a strategic reallocation of resources towards innovation.
- Revenue Diversification: Growth was broad-based with Women’s Health contributing 41% of total revenue, Oncology 39%, and Pharmacogenomics 20%, illustrating balanced portfolio expansion.
- Volume and Pricing Dynamics: Test volumes increased 4% in Q4 and 7% for the full year, supported by stable average selling prices and targeted commercial initiatives.
- Cost Management: Despite a 25% jump in R&D expenses, overall operating expense growth was controlled to a modest 3%, reflecting disciplined expense management amid strategic investments.
Overall, Myriad’s financial performance demonstrates a healthy balance between growth and profitability, positioning the company well to capitalize on market opportunities and offset reimbursement risks.
Executive Commentary
"We generated 11% revenue growth over 2023, making this our second consecutive year of double-digit growth, and $40 million in adjusted EBITDA. This achievement is the result of the company's multi-year investment strategy along with our team’s hard work and focus on the needs of our patients and the healthcare providers who serve them."
Paul J. Diaz, President and Chief Executive Officer
"Our growth will come from the increased focus on executing corporate programs that have the potential to drive material testing volume increase, including the breast cancer risk assessment program and EMR integration value realization. We will supplement our organic efforts with purposeful partnerships that enable us to serve high-growth, attractive market opportunities with speed."
Sam Raha, Chief Operating Officer
Strategic Positioning
1. AI-Driven Oncology Expansion
Myriad’s exclusive licensing agreement with Pathomic integrates advanced artificial intelligence into its oncology portfolio, particularly for prostate cancer. This multimodal approach combines molecular diagnostics with AI-powered image analysis to span the entire patient journey—from biopsy and active surveillance to post-surgical treatment decisions. This strategic move differentiates Myriad in a competitive market by offering comprehensive, guideline-aligned testing solutions, enhancing clinical utility and potentially accelerating evidence generation for Prolaris to achieve higher guideline recognition.
2. Strengthening Commercial Execution via EMR Integration
Investments in electronic medical record (EMR) integration have expanded Myriad’s commercial reach, with over 4,500 new clinic locations integrated across 15+ vendors including Athena and Epic. Although workflow disruptions have delayed volume ramp-ups in some health systems, these integrations are expected to fuel volume growth, particularly in the underpenetrated unaffected hereditary cancer market. This operational focus on seamless ordering and results delivery enhances customer experience and supports scalable growth.
3. Innovation Pipeline and Clinical Validation
Myriad is aggressively advancing its product pipeline with recent launches such as Prequel at eight weeks gestational age and upcoming products including FirstGene and Precise MRD. The company is investing heavily in clinical studies, with nearly 20 MRD trials underway involving over 4,000 patients, to validate clinical utility and support reimbursement. Strategic alliances, like the five-year collaboration with MD Anderson Cancer Center, further underscore Myriad’s commitment to evidence generation and market leadership in advanced diagnostics.
4. Navigating Reimbursement and Market Challenges
UnitedHealthcare’s decision to discontinue coverage for multi-gene panel pharmacogenetic testing poses a near-term revenue headwind, impacting approximately $45 million in 2024 revenue. Myriad is actively pursuing policy reversal and leveraging biomarker legislation advocacy to mitigate this risk. Despite this, GeneSight demand remains strong, supported by ongoing provider engagement and evidence publication, reflecting resilience in the pharmacogenomics segment.
5. Leadership Transition and Continuity
The appointment of COO Sam Raha as CEO effective April 30, 2025, signals leadership continuity focused on accelerating growth and innovation. The transition reflects confidence in the existing management team’s strategy execution and operational capabilities, with Chief Commercial Officer Mark Verratti promoted to COO to maintain commercial momentum.
Key Considerations
Myriad’s 2024 results highlight a company balancing growth, innovation, and operational discipline amid evolving market dynamics.
- Clinical Evidence Investment: Significant R&D spending supports new product launches and reimbursement positioning, essential for long-term growth.
- EMR Integration Complexity: While a critical growth driver, EMR workflow disruptions may delay volume ramp, requiring patience from investors.
- Reimbursement Risks: UnitedHealthcare’s policy change introduces uncertainty in pharmacogenomics revenue, necessitating strategic advocacy and operational adjustments.
- AI Partnership Upside: The Pathomic collaboration offers a unique competitive advantage in oncology diagnostics, potentially accelerating guideline adoption and market share gains.
- Leadership Stability: The CEO transition is well-planned, with internal promotions ensuring strategic continuity and execution focus.
Risks
Myriad faces risks from reimbursement policy shifts, particularly UnitedHealthcare’s coverage discontinuation of GeneSight, which could materially impact pharmacogenomics revenue if unresolved. Operational risks include EMR integration delays affecting volume growth and potential competitive pressures in oncology diagnostics. Additionally, the company’s ability to successfully commercialize and obtain reimbursement for new products like Precise MRD remains uncertain, dependent on clinical validation and payer acceptance.
Forward Outlook
For Q1 2025, Myriad guides revenue between $196 million and $204 million, anticipating a challenging year-over-year comparison due to prior favorable adjustments. Adjusted EPS is expected to range from a loss of $0.08 to $0.04 per share. For full-year 2025, management reaffirms guidance of $840 million to $860 million in revenue, gross margin between 69.5% and 70.5%, adjusted operating expenses of $575 million to $595 million, and adjusted EPS of $0.07 to $0.11. The company expects volume growth acceleration in the second half driven by EMR integration and new product contributions.
Takeaways
Myriad Genetics is strategically leveraging innovation, partnerships, and operational excellence to sustain growth and improve profitability despite reimbursement headwinds.
- Balanced Growth and Profitability: Sustained double-digit revenue growth coupled with margin expansion and positive adjusted EBITDA illustrates operational health and financial discipline.
- AI and Clinical Innovation as Growth Catalysts: The Pathomic AI partnership and robust clinical pipeline position Myriad to capture emerging oncology market opportunities and enhance competitive differentiation.
- Reimbursement and Execution Risks Require Monitoring: UnitedHealthcare policy changes and EMR integration complexities represent near-term challenges that could impact volume and revenue growth trajectories.
Conclusion
Myriad Genetics’ Q4 and full-year 2024 results demonstrate a company in transition, balancing innovation-driven growth with operational rigor and strategic partnerships. The leadership transition and reaffirmed 2025 guidance underscore management’s confidence in executing its multi-year strategy to advance precision medicine and deliver shareholder value.
Industry Read-Through
Myriad’s integration of AI into oncology diagnostics exemplifies a broader industry trend toward combining molecular testing with advanced computational tools to enhance clinical decision-making. The company’s experience navigating payer challenges highlights ongoing reimbursement complexities facing molecular diagnostics firms. Additionally, the emphasis on EMR integration as a volume growth driver signals a critical operational focus area for the diagnostics sector, with implications for competitor strategies and investment priorities.